Abstract 205P
Background
The real-life experience of radium-223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC) in Asia is limited. In recent ERA223 study, the post-treatment osteoporotic fracture risk was unexpectedly found elevated when Ra223 was given in addition to abiraterone/prednisone in mCRPC, raising a concern of long-term bone safety with Ra223.
Methods
Hospital records of consecutive patients with mCRPC treated with Ra223 in 5 Hong Kong public hospitals from Nov 2015 to Oct 2018 were retrieved for the analysis of treatment pattern and clinical outcomes.
Results
We identified 42 men with bony mCRPC (median age: 73; 78.6% ECOG PS 0/1; 61.9% with bone pain; 50% lymphadenopathy; 14.3% visceral metastases) who received at least 1 dose of Ra233 (median 6, IRQ: 4-6). Median follow-up was 8.8 months. Ra223 was administered at a median of 3rd line setting (IQR: 2nd to 4th line) with 88.1% and 35.7% having prior androgen-receptor axis-targeted agents (ARTAs, i.e. abiraterone and enzalutamide) and docetaxel. Ra223 was used concomitantly with ARTAs and bone health agents at 23.8% and 45.2%, respectively. 64.5% of patients had subsequent therapies (16.7% chemotherapy; 42.9% ARTAs). Median time to PSA progression was 3.6 months (IQR: 3.5-4.5) and 48.6% (18/37) had 30% drop of ALP after 3rd injection. 26.9% (7/26) with bone pain requiring analgesics had symptomatic improvement but 15% had worsened pain. 66.7% of patients were free from symptomatic skeletal event (SSE), with 6-month and 1-year SSE rates being 11.9% and 26.2%. The median OS was 18.2 months (95%CI: 4.6-31.9) and was longer for patients who received >4 injections (27.7 vs 7.8 months, p = 0.015). The most common AEs were anemia (67%), fatigue (36%), bone pain (33%), thrombocytopenia (26%) and neutropenia (19%). Treatment discontinuation due to AEs was 8%. Non-osteoporotic fracture was seen in 3 patients (2 pathological and 1 traumatic).
Conclusions
Later line use of Ra223 was a common real-life practice. Efficacy and tolerability with Ra223 remains favorable in heavily-pretreated mCRPC, despite higher rate of hematological AE was seen. With nearly ¼ patients with concomitant ARTAs, osteoporotic fracture was not seen in this cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract